Lupin gets DCGI nod for phase-II Desoris trials

Lupin has received approval from the Drug Controller General of India (DCGI) for phase II clinical trials of its investigational new drug candidate LLL-3348 (Desoris).

According to a release issued by Lupin to the BSE today, Desoris is prescribed for treatment of moderate to severe plaque-type psoriasis.

"Desoris is a herbal aqueous extract of a single plant that has a novel mechanism of action, and effectively modulates the cellular function leading to marked psoriatic lesion improvement without any toxic effects," the release added.